

**PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.**

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

**To automatically download images Add Sender to the Safe Senders List.**



## Research Awards & Funding Opportunities

June 6, 2021

Dear Research Community,

Below is a summary of COVID-19 funding opportunities recently released from the funding opportunity database SPIN. Click [here](#) for more information.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on [GCO's Funding Opportunities](#) page and on the [ORS Research Roadmap COVID-19 Funding Opportunities](#) page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in [The Conduit newsletter](#).

In addition, please review the [SPIN Getting Started Instructions](#) for information about beginning your individual search.

The Grants and Contracts Office



### SPIN Funding Opportunities 6/6/21

Links in the Project Title bring the user to more information in InfoEd > SPIN. To access those links, first log onto [InfoEd](#).

| SPIN ID      | Program Title  | Sponsor Name  | Sponsor Number   | Deadline Date   | Funding Amount |
|--------------|--|---|--|-----------------|----------------|
| 1.<br>093351 | <a href="#">FCO -- AMENDMENT -- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)</a> | Department of Health & Human Services   | BARDA  | BAA 31-Oct-2021 | Not Specified  |
|              | Contact Name   |   |  |                 |                |
|              | Contact Telephone  |   |  |                 |                |
|              | Contact Email  |   | <a href="mailto:BARDA-BAA@hhs.gov">BARDA-BAA@hhs.gov</a> |                 |                |
|              | Sponsor Website  |   | <a href="#">Link to sponsor website</a>                  |                 |                |
|              | Program URL  |   | <a href="#">Link to program URL</a>                      |                 |                |
|              | Deadline Dates (ALL)   |   | 31-Oct-2021  |                 |                |
|              | Synopsis   | Description We appreciate your interest in partnering with BARDA. Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue. Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest. BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement. Thank you for understanding this unprecedented response and delays that will occur. The latest BARDA Broad Agency Announcement (BAA) is amendment 16 posted on April 24, 2020. Note: COVID-19 response related Areas of Interest includes: AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection), Including Serology Tests AOI 8.3 COVID-19 Vaccine AOI 9.2 COVID-19 Therapeutics AOI 9.3 Immunomodulators or therapeutics targeting lung repair AOI 9.5 Pre-exposure and |  |                 |                |

post-exposure prophylaxis AOI 10 Respiratory protective devices AOI 11 Ventilators AOI 17 Advanced Manufacturing Technologies All contracting related inquiries should be sent to [BARDA-BAA@hhs.gov](mailto:BARDA-BAA@hhs.gov). BARDA clarified the language for rolling review of COVID-19 response related full proposals. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offeror should also complete the Submission Data Integration Table. The final white paper submission deadline is October 31, 2020. The final full proposal submission deadline is October 31, 2020 or as specified in the invitation letter. Additional beta.sam.gov information Notice Id 0bba3967c3404799aba43a1a9b3456ed Source <https://beta.sam.gov/opp/0bba3...>  
 Note: This link might not be valid after archive date below. Archive Date 10/31/2020

2. 104448 [COVID-19 Fund to Retain Clinical Scientists Request for Applications](#) Duke (Doris) Charitable Foundation 22-Jun-2021 [LOI/Pre-App] Not Specified
- Contact Name  
 Contact Telephone [212-974-7000](tel:212-974-7000)  
 Contact Email [ddcf@aibs.org](mailto:ddcf@aibs.org)  
 Sponsor Website [Link to sponsor website](#)  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 22-Jun-2021 [LOI/Pre-App], 20-Jul-2021
- Synopsis  
 The Doris Duke Charitable Foundation, together with the Burroughs Wellcome Fund, Rita Allen Foundation, and Walder Foundation, believe that this is a key moment to accelerate long needed culture change for academia to become more inclusive of scientists with family caregiving needs. The sponsors have come together to support and spotlight changes at the institutional level that can support scientists with family caregiving needs, focusing on early-career physician scientists working at U.S. medical schools. This is a workforce ripe to benefit from institutional action and proximate to the public health concerns that are front and center during the pandemic. Building on the promising outcomes of the Doris Duke Fund to Retain Clinical Scientists program, the Doris Duke Charitable Foundation and its partners are allocating up to \$10 million to award one-time institutional grants of \$500,000 total direct cost plus 10% indirect costs over two years to U.S. medical schools that are evolving to strengthen policies, practices, and processes to support the research productivity of early-career faculty with family caregiving responsibilities. The majority of the grants are earmarked to support institutional programs providing research supplements for physician scientists working on clinical research projects whose productivity is being impacted by family caregiving responsibilities increased by COVID-19. The goal of the research supplements will be to enable recipients to regain research productivity and momentum, and to prevent their attrition from research. Supplement candidates must be early faculty who are working on significant biomedical problems. They must have active financial support, whether intra or extramural, for their main research and be on a clear trajectory to a successful independent research career. Importantly, they must be able to articulate how the supplement would enable them to maintain research productivity in light of family caregiving responsibilities augmented by COVID-19. The supplemental funds from the Fund to Retain Clinical Scientists would typically be used to support temporary technical assistance. Funding has been earmarked to support at least two grants to minority-serving U.S. medical schools.
3. 104325 [RFA-DA-22-005 -- Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory \(R21 - Clinical Trial Not Allowed\)](#) National Institute on Drug Abuse/NIH/DHHS RFA-DA-22-005 14-Sep-2021 [Optional] [LOI/Pre-App] 275,000 USD
- Contact Name Vani Pariyadath, Ph.D.  
 Contact Telephone [301-443-3209](tel:301-443-3209)  
 Contact Email [vani.pariyadath@nih.gov](mailto:vani.pariyadath@nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 14-Sep-2021 [Optional][LOI/Pre-App], 14-Oct-2021
- Synopsis  
 This funding opportunity announcement (FOA) invites mechanistic studies on the impact of social inequality on the brain and on the substance use trajectory. Applications investigating relevant mechanisms at the behavioral, cognitive, neurocircuitry, cellular, genetics, and epigenetics levels are encouraged. Exploratory and high-risk research projects are appropriate for this FOA. Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data should consider applying to the companion R01 announcement RFA-DA-22-007.
4. 104327 [RFA-DA-22-024 -- Mechanistic Studies on the](#) National Institute on RFA-DA- 14-Sep-2021 Not

Contact Name Vani Pariyadath, Ph.D.  
 Contact Telephone [301-443-3209](tel:301-443-3209)  
 Contact Email [vani.pariyadath@nih.gov](mailto:vani.pariyadath@nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 14-Sep-2021 [Optional][LOI/Pre-App], 14-Oct-2021

Synopsis This funding opportunity announcement (FOA) invites mechanistic studies on the impact of social inequality on the brain and on the substance use trajectory. Applications investigating relevant mechanisms at the behavioral, cognitive, neurocircuitry, cellular, genetics, and epigenetics levels are encouraged. Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data are appropriate for this FOA. Applicants with exploratory and high-risk research projects should consider applying to the companion R01 announcement RFA-DA-22-030.

5. [RFA-DA-22-030 -- Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory \(R21 - Basic Experimental Studies with Humans Required\).](#) National Institute on Drug Abuse/NIH/DHHS RFA-DA-22-030 14-Sep-2021 [Optional][LOI/Pre-App] 275,000 USD

Contact Name Vani Pariyadath, Ph.D.  
 Contact Telephone [301-443-3209](tel:301-443-3209)  
 Contact Email [vani.pariyadath@nih.gov](mailto:vani.pariyadath@nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 14-Sep-2021 [Optional][LOI/Pre-App], 14-Oct-2021

Synopsis This funding opportunity announcement (FOA) invites mechanistic studies on the impact of social inequality on the brain and on the substance use trajectory. Applications investigating relevant mechanisms at the behavioral, cognitive, neurocircuitry, cellular, genetics, and epigenetics levels are encouraged. Exploratory and high-risk research projects are appropriate for this FOA. Applicants with projects testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data should consider applying to the companion R01 announcement RFA-DA-22-024.

6. [Notice of Special Interest \(NOSI\): Administrative Supplements to NIMHD Awards for Research on HIV/AIDS in Populations that Experience Health Disparities \(Admin Supp Clinical Trial Optional\).](#) National Institute on Minority Health and Health Disparities/NIH/DHHS NOT-MD-21-020 Continuous Submission Not Specified

Contact Name Priscilla Grant, JD  
 Contact Telephone [301-594-8412](tel:301-594-8412)  
 Contact Email [pg38h@nih.gov](mailto:pg38h@nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL)

Synopsis NIMHD is soliciting supplements to active NIMHD grants and cooperative agreements to support research on HIV/AIDS in NIH-designated populations that experience health disparities, including Blacks or African Americans, Hispanics or Latinos, American Indians and Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, socioeconomically disadvantaged populations, underserved rural populations, and sexual and gender minorities. The purpose of this NOSI is to emphasize the continued importance of conducting research on HIV/AIDS that will further the EHE effort, including but not limited to research on how the COVID-19 pandemic and structural racism and discrimination affect HIV risk, prevention, and treatment among populations that experience health disparities.

7. [Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities \(R01 Clinical Trial Optional\).](#) National Institutes of Health/DHHS PA-21-232 05-Oct-2021 2,500,000 USD

Contact Name Larissa Aviles-Santa, MD, MPH  
 Contact Telephone [301-827-6924](tel:301-827-6924)  
 Contact Email [avilessantal@mail.nih.gov](mailto:avilessantal@mail.nih.gov)  
 Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024

Synopsis This initiative will support innovative research to develop, test and evaluate multi-level/multi-component strategies (including models of health care) to effectively adapt and implement comprehensive clinical care for individuals with Type 2 diabetes mellitus from populations with health disparities concordant with recommended and evidence-based guidelines.

8. 104370 [Rural Health Clinic Vaccine Confidence Program](#) Office of Rural Health Policy/HRSA/DHHS HRSA-21-142 23-Jun-2021 50,000 USD

Contact Name Lindsey Nienstedt  
 Contact Telephone [301-443-0835](tel:301-443-0835)  
 Contact Email [RHCVaxConfidence@hrsa.gov](mailto:RHCVaxConfidence@hrsa.gov)  
 Sponsor Website [Link to sponsor website](#)  
 Program URL  
 Deadline Dates (ALL) 23-Jun-2021

Synopsis The Health Resources and Services Administration (HRSA) is accepting applications for the fiscal year (FY) 2021 Rural Health Clinic Vaccine Confidence (RHCVC) Program. The purpose of this program is to address COVID-19 related health equity gaps and improve health care in rural areas by engaging Rural Health Clinics (RHCs) to improve vaccine confidence and counter vaccine hesitancy in rural communities.

**Icahn School of Medicine at Mount Sinai**  
 1 Gustave L. Levy Place, New York  
 NY 10029 United States

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.  
 This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.